Logo

Acrongenomics Begins Private Placement Financing

Nov 22, 2004

NEW YORK, Nov. 22 (GenomeWeb News) - Acrongenomics, formerly Cellway Ventures, said last week that it is beginning a private placement financing for 400,000 of its shares at $2.50 per share.

 

The company said that a finders fee of 10 percent in stock will be paid upon the closing of the financing round.

 

Acrongenomics said it plans to use the proceeds of the financing to support ongoing validation studies of its first product, the NeoEpCam cancer detection kit.

 

Breaking News
The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.